Bear of the Day: Centene (CNC)

Centene (CNC) unexpectedly withdrew its 2025 earnings guidance on July 2, citing an unforeseen shift in health insurance marketplace dynamics characterized by higher-than-expected market morbidity and slower growth. This is projected to cause a $1.8 billion shortfall in net risk adjustment revenues, translating to a $2.75 impact on 2025 adjusted diluted EPS. In response, Wall Street analysts have drastically cut EPS projections, with Zacks consensus halved to $3.55, and Wells Fargo downgraded the stock, slashing its price target from $72 to $30. Centene is now proactively adjusting its 2026 rates to account for this higher morbidity baseline, signaling a more defensive pricing strategy.

Analysis

Centene (CNC) has unexpectedly withdrawn its 2025 earnings guidance, signaling a significant deterioration in its Health Insurance Marketplace business outlook. The decision stems from actuarial data across 72% of its Marketplace membership, which revealed higher-than-expected market morbidity and slower growth, leading to a projected $1.8 billion shortfall in net risk adjustment revenues. This translates to a direct negative impact of $2.75 on 2025 adjusted diluted EPS, with management anticipating further declines from the remaining states. The market reaction has been severe, with the Zacks profit consensus being halved from $7.29 to $3.55 and Wells Fargo downgrading the stock to Equal-Weight while slashing its price target to $30 from $72. While the company noted that its 2024 results were in line and its Medicare Advantage and PDP segments are outperforming in Q2 2025, these positives are overshadowed by the Marketplace issues and rising costs in its Medicaid business. In response, Centene is defensively refiling its 2026 rates to account for the higher morbidity baseline, a necessary but long-term measure that does not address the immediate 2025 earnings collapse. The upcoming Q2 2025 earnings release on July 25 is now a critical event for further clarity.

Key Decisions for Investors

• Given the withdrawal of 2025 guidance and substantial uncertainty, investors should treat the upcoming July 25 earnings report as a critical catalyst for gaining clarity on the full financial impact and management's mitigation strategy.
• The significant downward revision in analyst estimates and price targets signals a fundamental re-rating of the stock, warranting a re-evaluation of long-term investment theses based on the new reality of a higher-morbidity risk pool.
• Investors should closely monitor the performance of Centene's Medicare Advantage and PDP segments, as their reported outperformance may provide a partial, albeit insufficient, offset to the severe pressures in the Marketplace and Medicaid businesses.
• Consider the proactive rate adjustments for 2026 as a necessary defensive action, but recognize that this addresses future profitability and does not resolve the significant earnings shortfall expected for 2025.